Infinity Pharmaceuticals

Infinity Pharmaceuticals

Biotechnology company focused on discovery and development of treatments for cancer and other related conditions

Infinity Pharmaceuticals is a Cambridge based Biotechnology Company working towards the discovery and development of treatments for cancer. The company’s lead product candidate, IPI-549 is an oral drug which selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma). PI3K-gamma is a signal-transducing enzyme which is a critical modulator in cancer and immunity. As of March 2019, the drug is being studied for activity, safety, tolerability, pharmacokinetics, and pharmacodynamics.

Product

IPI-549 is being developed to inhibit the growth of cancer tumors. Research by the company has demonstrated transcriptional reprogramming of tumor-related macrophages by blocking PI3K-gamma signaling. It showed promise in promoting anti-tumor immune response by reprogramming pro-tumor phenotype to anti-tumor phenotype in the tumor microenvironment.

The drug is tested for use as monotherapy and in combination therapy with a PD-1 immune checkpoint inhibitor called nivolumab. The test study includes four parts; monotherapy and combination dose-escalation components with monotherapy expansion and combination expansion components. Approximately 200 patients with advanced cancer tumors relating to non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and triple negative breast cancer (TNBC) were selected as a part of this study. In combination expansion component study, the drug was evaluated with cancer patients suffering from NSCLC, HNSCC, and melanoma whose tumors show resistance to immune checkpoint blockade therapy.

History

Eric Lander, Frank Moss, and Michael Foely founded the company in 2001, and the company is headquartered in Cambridge, Massachusetts, United States.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Infinity Pharmaceuticals funding round, November 2011
50,000,000
November 29, 2011
2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Adriano Varassin

Employee

Andrea Lai

Employee

Andy Palmer

Employee

Andy Palmer

Employee

Chelsey Jensen

Employee

Daniela Lopez

Employee

David Drucker

Employee

David Michael Marks

Employee

David Nick

Employee

dennis underwood

Employee

Dennis Underwood

Employee

Igor Deyneko

Employee

Jamie Manning

Employee

Jarrett Goetz

Employee

Kevin Gilpin

Employee

MEGAN MOORE

Employee

Shawnise Beatty

Employee

Stephen Jamieson

Employee

Tiffany Ann Chen

Employee

Vaden Broaddus

Employee

Further reading

Title
Author
Link
Type
Date

IPI-549 - Infinity Pharmaceuticals, Inc

Infinity Pharmaceuticals

Web

PI3K-Gamma - Infinity Pharmaceuticals, Inc

Infinity Pharmaceuticals

Web

Documentaries, videos and podcasts

Title
Date
Link

Infinity Pharmaceuticals CEO on New Cancer Drug (6/03/13)

Jun 4, 2013

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Infinity Pharmaceuticals, Inc.
May 7, 2019
www.prnewswire.com:443
CAMBRIDGE, Mass., May 7, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its first quarter 2019 financial results and...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.